Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 7.2M | 39.8% |
| Operating expense | 36M | 15.1% |
| Net Income | -26M | 23.9% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 320M | 8.6% |
| Total Liabilities | 124M | 6.9% |
| Total Equity | 195M | 9.7% |
| Shares Outstanding | 71M | 0.5% |
Cash Flow (USD)
| Q1 '25 | QoQ |
|---|
EPS
Financial Highlights for C4 Therapeutics in Q1 '25
C4 Therapeutics reported a revenue of 7.2M, which is a 39.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Operating Expenses for this period were 36M, showing a -15.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -26M, showing a 23.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
C4 Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
